Drug Trial Radar · NCT06978244
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Jul 29, 2025
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- May 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Single-Center, Phase 1 study to assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
Conditions
- Ocular Pain
Interventions
BL1332 ophthalmic solutionDrug
Both arms taken four times a day for 1 day
BL1332 ophthalmic vehicleDrug
Both arms taken four times a day for 1 day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTs (dose-limiting toxicities)Time frame: Approximately 6 months
- Incidence of treatment-emergent AEs (TEAEs)Time frame: Approximately 6 months
- Treatment-emergent changes in systemic and ocular safety assessmentsTime frame: Approximately 6 months
- PK profiles and following parameter, where data allow (Cmax)Time frame: Approximately 6 months
- PK profiles and following parameter, where data allow ( Tmax)Time frame: Approximately 6 months
- PK profiles and following parameter, where data allow (Ctau)Time frame: Approximately 6 months
- PK profiles and following parameter, where data allow (Tlast)Time frame: Approximately 6 months
- PK profiles and following parameter, where data allow ( AUClast)Time frame: Approximately 6 months
- PK profiles and following parameter, where data allow (AUCtau)Time frame: Approximately 6 months
- PK profiles and following parameter, where data allow (AUCinf)Time frame: Approximately 6 months
- PK profiles and following parameter, where data allow (ke1)Time frame: Approximately 6 months
- PK profiles and following parameter, where data allow (t1/2)Time frame: Approximately 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 101
Fair Lawn, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.